Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer

Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR) activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are mainstay treatments for CRPC; however patients eventually progress with ENZ resistant (ENZR) disease. In this study, we in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Shiota, Masaki, Bishop, Jennifer L., Takeuchi, Ario, Nip, Ka Mun, Cordonnier, Thomas, Beraldi, Eliana, Kuruma, Hidetoshi, Gleave, Martin E., Zoubeidi, Amina
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2015
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4496204/
https://ncbi.nlm.nih.gov/pubmed/25871401
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk